These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 17726933)

  • 41. Medical treatment of canine hyperadrenocorticoidism with o,p'-DDD.
    Lorenz MD; Scott DW; Pulley LT
    Cornell Vet; 1973 Oct; 63(4):646-65. PubMed ID: 4748884
    [No Abstract]   [Full Text] [Related]  

  • 42. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
    Mantis P; Lamb CR; Witt AL; Neiger R
    Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism.
    Kenefick SJ; Neiger R
    J Small Anim Pract; 2008 Mar; 49(3):139-43. PubMed ID: 18086154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.
    Peterson ME; Kintzer PP
    Vet Clin North Am Small Anim Pract; 1997 Mar; 27(2):255-72. PubMed ID: 9076906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism.
    Hurley KJ; Vaden SL
    J Am Vet Med Assoc; 1998 Feb; 212(3):369-73. PubMed ID: 9470045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
    Braddock JA; Church DB; Robertson ID; Watson AD
    Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986).
    Nelson RW; Ihle SL; Feldman EC
    J Am Vet Med Assoc; 1989 Jun; 194(11):1612-7. PubMed ID: 2753785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective evaluation of the effect of trilostane on insulin requirement and fructosamine concentration in eight diabetic dogs with hyperadrenocorticism.
    McLauchlan G; Knottenbelt C; Augusto M; Helm J; McGrotty Y; Ramsey I
    J Small Anim Pract; 2010 Dec; 51(12):642-8. PubMed ID: 21121919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of the urine cortisol: creatinine ratio to monitor treatment response in dogs with pituitary-dependent hyperadrenocorticism.
    Guptill L; Scott-Moncrieff JC; Bottoms G; Glickman L; Johnson M; Glickman N; Nelson R; Bertoy E
    J Am Vet Med Assoc; 1997 Apr; 210(8):1158-61. PubMed ID: 9108922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism.
    Rijnberk A; Belshaw BE
    Vet Rec; 1988 May; 122(20):486-8. PubMed ID: 3420770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
    Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
    J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of canine hyperadrenocorticism, using computed tomography.
    Emms SG; Wortman JA; Johnston DE; Goldschmidt MH
    J Am Vet Med Assoc; 1986 Aug; 189(4):432-9. PubMed ID: 3019972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Vaughan MA; Feldman EC; Hoar BR; Nelson RW
    J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs.
    Nagata N; Yuki M
    Can Vet J; 2015 Sep; 56(9):931-3. PubMed ID: 26347041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism.
    Braddock JA; Church DB; Robertson ID; Watson AD
    Aust Vet J; 2004 May; 82(5):272-7. PubMed ID: 15181926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane.
    Reusch CE; Sieber-Ruckstuhl N; Wenger M; Lutz H; Perren A; Pospischil A
    Vet Rec; 2007 Feb; 160(7):219-24. PubMed ID: 17308018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism.
    Dunn KJ; Herrtage ME; Dunn JK
    Vet Rec; 1995 Aug; 137(7):161-5. PubMed ID: 8553523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased insulin sensitivity and glucose tolerance in spontaneous canine hyperadrenocorticism.
    Peterson ME; Altszuler N; Nichols CE
    Res Vet Sci; 1984 Mar; 36(2):177-82. PubMed ID: 6371957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperadrenocorticism associated with excessive sex hormone production by an adrenocortical tumor in two dogs.
    Syme HM; Scott-Moncrieff JC; Treadwell NG; Thompson MF; Snyder PW; White MR; Oliver JW
    J Am Vet Med Assoc; 2001 Dec; 219(12):1725-8, 1707-8. PubMed ID: 11767922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis.
    Benchekroun G; de Fornel-Thibaud P; Lafarge S; Gomez E; Begon D; Delisle F; Moraillon R; Héripret D; Maurey C; Rosenberg D
    Vet Rec; 2008 Aug; 163(6):190-2. PubMed ID: 18689782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.